- The new cGMP filling line at Stein (CH) will be operational in 2027.
- Approximately 115 new jobs will be created at peak capacity.
- The project follows a CHF 500 million investment in Stein and Visp facilities.
- The ADC market is expected to grow at a CAGR of 20% from 2023 to 2028.
New cGMP Filling Line
Lonza will construct a dedicated commercial-scale aseptic cGMP filling line at its Stein (CH) site. This new line will handle the aseptic filling of highly-potent antibody-drug conjugates (ADCs) and lyophilization under containment. The facility is expected to be operational in 2027 and will create approximately 115 new jobs at peak capacity.
Expansion of Capabilities
The new filling line will enhance Lonza's end-to-end integrated offering for manufacturing ADC drug substances and drug products. This expansion builds upon a successful multi-year relationship with a major biopharmaceutical partner, covering the manufacturing of highly-potent payloads, drug-linker and conjugation services, and large-scale supply of monoclonal antibodies (mAbs).
Investment and Growth
This project follows the recent completion of a filling line in Visp (CH) and the groundbreaking of a large-scale commercial filling facility in Stein (CH), supported by an investment of approximately CHF 500 million. The additional filling capabilities will further strengthen Lonza's capacity and flexibility in supporting both clinical and commercial supply of bioconjugates.
Market Outlook
The value of the total bioconjugates market is currently USD 33 billion, with the ADC market valued at USD 10 billion. The ADC market is expected to grow at a compound annual growth rate (CAGR) of 20% between 2023 and 2028. As a leading CDMO for bioconjugates, Lonza has produced over 1,000 cGMP batches for more than 70 programs since 2006, offering an integrated solution for drug substance and drug product development, manufacturing, and filling.
